Rare Mutations and Fusions Patient Gateway

About rare mutations and fusions in lung cancer

Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.

Learn More

LATEST UPDATES

Find your Community

Whether you're living with lung cancer, or caring for someone with the disease, online groups and biomarker-specific communities can offer much-needed support.

Find your Community

Learn about
Clinical Trials

Participating in a research study may offer additional treatment options for those who are eligible.

Learn about Clinical Trials

Find a Specialist

Locate a healthcare provider who specializes in your specific type of cancer

Find a Specialist

Sponsors

AstraZeneca

 

Boehringer Ingelheim

 

Bristol Myers Squibb

 

Janssen

 

Novartis

 

Takeda